Can-Fite BioPharma Ltd. (NYSE:CANF) traded at $2.2966 at last check on Monday, June 29, making an upward move of 7.71% on its previous day’s price.
Looking at the stock we see that its previous close was $1.88 and the beta (5Y monthly) reads 1.09 with the day’s price range being $1.9600 – 2.0700. In terms of its 52-week price range, CANF has a high of $4.95 and a low of $1.08. The company’s stock has gained about -8.29% over that past 30 days.
On the other hand, looking at the outlook for the CANF stock, short term indicators assign the stock an average of Hold, while medium term indicators assign it an average of Hold. Long term indicators on average place the stock in the category of 50% Sell.
Based on estimates by 2 analysts where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, none have rated the Can-Fite BioPharma Ltd. (CANF) stock as a Hold, while 2 rate it as a Buy. None analysts rate it as outperform while none of them rated it as underperform, whereas none suggests the stock as a Sell. The stock has an overall rating of Buy and investors could take advantage and scoop up stock of the company.
Looking further, we note that the PEG ratio for the CANF stock currently stands at 0, and the current price level is 7.97% off its SMA20 and 7.51% from its 50-day simple moving average. The RSI (14) is pointing at 57.4 while the volatility over the past week is 5.28% and jumps to 7.78% over the past one month. The beta value is 0, while the average true range (ATR) is currently pointing at 0.17. The average price target for the stock over the next 12 months is $6, with the estimates having a low of $5 and a high of $7. These price ends are 117.71% and +204.8% off the current price level respectively, although investors could be excited at the prospect of a +161.26% if the CANF share price touches on the median price of $6.
Let’s briefly compare Can-Fite (CANF) stock to its peers. We find that today’s price change of +7.71% and -37.95% over the past 12 months for CANF competes that of Zoetis Inc Cl A (ZTS), which has seen its stock price fall -0.01% in the latest trading session and is +17.65% over the last one year. Another of its peers Takeda Pharmaceutical Co. Ltd (TAK) has dropped -1.42% today, and is +4.38% up over the past year, while Grifols S.A. (GRFS) is also up 7.71% yet its price remains in the red at -37.95% over the same period. Zoetis has a P/E ratio of 39.46 compared to Can-Fite’s 0 and Takeda’s 22.6. In contrast to these companies, both the S&P 500 Index and the Dow Jones Industrial are today at 1.81% and 1.11%, respectively, in early deals.
Coming back to Can-Fite BioPharma Ltd. (NYSE:CANF), we note that the average 3-month trading volume was 1.04 Million, while that of the preceding 10-day period stands at 775.18 Million. Current shares outstanding are 13.71 Million.
According to data from Thomson Reuters, insiders hold 1.99% of the company’s shares while institutions hold 9.22%. The data shows that short shares as of June 14, 2020, stood at 166.49 Million at a short ratio of 0.12. This represents a 1.21% Short interest in Shares outstanding on June 14, 2020. Shares short dropped in June from the previous month at 211.01 Million. Investors should be excited about this stock as its upside potential is great, with today’s price pushing the stock -43.03% down in year-to-date price movement.